/AARD
AARD Stock - Aardvark Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$13.77+0.58%
+$0.08 (+0.58%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+52.5%upside
Target: $21.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AARD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.63 – $13.91
TARGET (TP)$21.00
STOP LOSS$12.67
RISK/REWARD1:6.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.62
52W High$19.58
52W Low$4.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-22,785,000 | $-7,415,000 | $-11,363,000 |
| Net Income | $-20,588,000 | $-7,208,000 | $-13,564,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-1.59 | $-0.56 | $-1.39 |
Company Overview
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
1
14%
Buy / Outperform
6
86%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$32
Average Target
↑ 135.1% Upside
Now
$21
Low
$32
Average
$50
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | William Blair | Initiation | Outperform | - |
| December 3rd 2025 | Raymond James | Initiation | Strong Buy | $47 |
| November 7th 2025 | BTIG Research | Initiation | Buy | $26 |
| September 29th 2025 | Stifel | Initiation | Buy | $24 |
| June 30th 2025 | H.C. Wainwright | Initiation | Buy | $40 |
| March 10th 2025 | Morgan Stanley | Initiation | Overweight | $29 |
| March 10th 2025 | BofA Securities | Initiation | Buy | $22 |
| March 10th 2025 | RBC Capital Mkts | Initiation | Outperform | $21 |
| March 10th 2025 | Cantor Fitzgerald | Initiation | Overweight | $50 |
Earnings History & Surprises
AARDBeat Rate
50%
Last 2 quarters
Avg Surprise
-9.2%
EPS vs Estimate
Beats / Misses
1/1
Last 12 quarters
Latest EPS
$-0.75
Q4 2025
EPS Surprise History
Q4 23
No data
Q3 25
-26.9%
$-0.66vs$-0.52
Q4 25
+8.5%
$-0.75vs$-0.82
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.82 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.82 | $-0.75 | +8.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.52 | $-0.66 | -26.9% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-0.14 | — | — |
Latest News
William Blair Initiates Coverage On Aardvark Therapeutics with Outperform Rating
📈 PositiveBenzinga•Dec 12, 2025, 04:27 PM
Aardvark Therapeutics Doses First Patient In Australia In HERO Phase 3 Trial For Prader-Willi Syndrome
📈 PositiveBenzinga•Dec 10, 2025, 09:38 PM
RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 14, 2025, 03:37 PM
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:32 PM
BTIG Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $26
📈 PositiveBenzinga•Nov 7, 2025, 11:31 AM
Aardvark Therapeutics Presents Data At ObesityWeek 2025 Demonstrating Mechanistic Rationale And Therapeutic Potential Of Two Metabolic Obesity Programs, Including ARD-201
📈 PositiveBenzinga•Nov 4, 2025, 05:02 PM
Reported Earlier: Aardvark Therapeutics Announces Alignment With The FDA On A Protocol Amendment To The Company's Phase 3 Hero Trial Of ARD-101 For The Treatment Of Hyperphagia Associated With Prader-Willi Syndrome
📈 PositiveBenzinga•Oct 8, 2025, 02:10 PM
Jones Trading Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $33
📈 PositiveBenzinga•Oct 1, 2025, 10:45 AM
Stifel Initiates Coverage On Aardvark Therapeutics with Buy Rating, Announces Price Target of $24
📈 PositiveBenzinga•Sep 29, 2025, 02:49 PM•Also:
HC Wainwright & Co. Reiterates Buy on Aardvark Therapeutics, Maintains $40 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 11:15 AM
B of A Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $25
➖ NeutralBenzinga•Aug 28, 2025, 03:50 PM
Aardvark Therapeutics Reports Q2 Loss
📉 NegativeThe Motley Fool•Aug 13, 2025, 09:04 PM
Frequently Asked Questions about AARD
What is AARD's current stock price?
Aardvark Therapeutics, Inc. Common Stock (AARD) is currently trading at $13.77 per share. The stock has moved +0.58% today.
What is the analyst price target for AARD?
The average analyst price target for AARD is $21.00, based on 1 analyst.
What sector is Aardvark Therapeutics, Inc. Common Stock in?
Aardvark Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AARD's market cap?
Aardvark Therapeutics, Inc. Common Stock has a market capitalization of $0.30 billion, making it a small-cap company.
Does AARD pay dividends?
No, Aardvark Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
AVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to AARD for comparison